DURECT Corporation (DRRX)

NASDAQ: DRRX · IEX Real-Time Price · USD
1.590
+0.140 (9.66%)
At close: Jul 19, 2024, 4:00 PM
1.550
-0.040 (-2.52%)
After-hours: Jul 19, 2024, 6:49 PM EDT
9.66%
Market Cap 49.35M
Revenue (ttm) 8.32M
Net Income (ttm) -23.28M
Shares Out 31.04M
EPS (ttm) -0.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 98,400
Open 1.430
Previous Close 1.450
Day's Range 1.430 - 1.650
52-Week Range 0.470 - 3.600
Beta 1.03
Analysts Buy
Price Target 23.00 (+1,346.54%)
Earnings Date Aug 7, 2024

About DRRX

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company’s lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osm... [Read more]

Sector Healthcare
IPO Date Sep 28, 2000
Employees 58
Stock Exchange NASDAQ
Ticker Symbol DRRX
Full Company Profile

Financial Performance

In 2023, DURECT's revenue was $8.55 million, a decrease of -55.67% compared to the previous year's $19.28 million. Losses were -$27.62 million, -21.82% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DRRX stock is "Buy." The 12-month stock price forecast is $23.0, which is an increase of 1,346.54% from the latest price.

Price Target
$23.0
(1,346.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

DURECT plans to confirm the efficacy and safety of larsucosterol in a registrational Phase 3 clinical trial  CUPERTINO, Calif. , May 21, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-...

2 months ago - PRNewsWire

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update

-         FDA Feedback Supports Single Pivotal Trial for Approval of Larsucosterol in Alcohol-Associated Hepatitis -         Webcast of Earnings Call Today, May 13th at 4:30 p.m. ET CUPERTINO, Calif.

2 months ago - PRNewsWire

DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update

CUPERTINO, Calif. , May 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment ...

2 months ago - PRNewsWire

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

CUPERTINO, Calif. , April 30, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatme...

2 months ago - PRNewsWire

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

- Ongoing Communication with FDA to Align on Next Steps for Larsucosterol in Alcohol-Associated Hepatitis - Webcast of Earnings Call Today, March 27th at 4:30 p.m. ET CUPERTINO, Calif.

4 months ago - PRNewsWire

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

CUPERTINO, Calif. , March 20, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatme...

4 months ago - PRNewsWire

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly m...

4 months ago - PRNewsWire

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

CUPERTINO, Calif. , Feb. 7, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.

5 months ago - PRNewsWire

Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: AADIKTRA
7 months ago - Benzinga

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

-  Webcast of Earnings Call Today, November 13th at 4:30 p.m. ET -  Topline data from AHFIRM trial showed compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortalit...

8 months ago - PRNewsWire

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

CUPERTINO, Calif. , Nov. 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment...

9 months ago - PRNewsWire

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days.  Clinically relevant reduction in 90-day mortality of 41% for 30 mg dose and 35% for 90 mg d...

9 months ago - PRNewsWire

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Company on track to report topline data from AHFIRM in Q4 2023 CUPERTINO, Calif. , Sept. 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering th...

11 months ago - PRNewsWire

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

CUPERTINO, Calif. , Aug. 31, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver disease...

11 months ago - PRNewsWire

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

-    Webcast of Earnings Call Today, August 9th at 4:30 p.m. ET -    Topline data from AHFIRM trial expected in Q4 2023 CUPERTINO, Calif.

1 year ago - PRNewsWire

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

CUPERTINO, Calif. , Aug. 3, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases...

1 year ago - PRNewsWire

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

CUPERTINO, Calif. , July 20, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of ...

1 year ago - PRNewsWire

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Topline data anticipated in Q4 2023 CUPERTINO, Calif. , June 7, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of...

1 year ago - PRNewsWire

DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update

- Webcast of Earnings Call Today, May 8th at 4:30 p.m. ET - Topline data from AHFIRM trial expected in 2H 2023 CUPERTINO, Calif.

1 year ago - PRNewsWire

DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8

CUPERTINO, Calif. , May 1, 2023 /PRNewswire/ --- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the mar...

1 year ago - PRNewsWire

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

CUPERTINO, Calif., April 27, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New Y...

1 year ago - PRNewsWire

DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

CUPERTINO, Calif. , April 25, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Man...

1 year ago - PRNewsWire

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

Data expands upon previously reported results, including individual patient data, additional liver biomarkers, and comparisons to matching arms from a contemporaneous study

1 year ago - PRNewsWire

DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

CUPERTINO, Calif. , March 21, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.

1 year ago - PRNewsWire

DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

CUPERTINO, Calif. , March 9, 2023 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will participa...

1 year ago - PRNewsWire